Fax: (405) 271-2976
Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?†‡
A Gynecologic Oncology Group ancillary data analysis
Article first published online: 24 AUG 2010
Copyright © 2010 American Cancer Society
Volume 116, Issue 23, pages 5407–5414, 1 December 2010
How to Cite
Moore, K. N., Tian, C., McMeekin, D. S., Thigpen, J. T., Randall, M. E. and Gallion, H. H. (2010), Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?. Cancer, 116: 5407–5414. doi: 10.1002/cncr.25480
Presented at the Gynecologic Oncology Group Meeting, Garden Grove, California, January 22-25, 2009, and as a plenary presentation at the Society of Gynecologic Oncologists Annual Meeting, San Antonio, Texas, February 5-8, 2009.
The following Gynecologic Oncology Group member institutions participated in the primary treatment studies: Wake Forest University School of Medicine, Columbus Cancer Council, University of California Medical Center at Irvine, Duke University Medical Center, Wayne State University, Indiana University Medical Center, University of Kentucky, Washington University School of Medicine, Abington Memorial Hospital, University of Iowa Hospitals and Clinics, Tufts-New England Medical Center, University of Mississippi Medical Center, Milton S. Hershey Medical Center, Rush-Presbyterian-St. Luke's Medical Center, Albany Medical College, University of Texas Southwestern Medical Center at Dallas, Community Clinical Oncology Program, University of Oklahoma, University of Minnesota Medical School, University of Virginia, Cleveland Clinic Foundation, University of Alabama at Birmingham, Colorado Gynecologic Oncology Group, University of North Carolina School of Medicine, University of Massachusetts Medical School, Fox Chase Cancer Center, Women's Cancer Center, State University of New York at Stony Brook, Medical University of South Carolina, Johns Hopkins Oncology Center, Cooper Hospital/University Medical Center, University of Chicago, Walter Reed Army Medical Center, Tampa Bay Cancer Consortium, University of Rochester Medical Center, Eastern Pennsylvania Gynecology/Oncology Center, Tacoma General Hospital, Thomas Jefferson University Hospital, Case Western Reserve University, University of Cincinnati, University of Pennsylvania Cancer Center, Gynecologic Oncology Network, Georgetown University Hospital, Mayo Clinic, Oregon Health Sciences University, University of Miami School of Medicine, University of California at Los Angeles, State University of New York Upstate Medical Center, Eastern Virginia Medical School, The University of Texas M. D. Anderson Cancer Center, Ellis Fischel Cancer Center, State University of New York Downstate Medical Center, Emory University Clinic, University of Southern California at Los Angeles, Stanford University Medical Center, Memorial Sloan-Kettering Cancer Center, University of Washington, North Shore University Hospital, and Long Island Jewish Medical Center.
- Issue published online: 23 NOV 2010
- Article first published online: 24 AUG 2010
- Manuscript Accepted: 11 MAY 2010
- Manuscript Revised: 8 MAY 2010
- Manuscript Received: 16 DEC 2009
- 23Regression models and life-tables. J R Stat Soc B. 1972; 34: 187-220.
- 25A phase II evaluation of bevacizumab in the treatment of recurrent or persistent endometrial cancer: a GOG study [abstract]. J Clin Oncol. 2009; 27( 15S pt I): 284S. Abstract 5531., , , et al.